Cargando…

Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model

BACKGROUND: Spinocerebellar ataxia type 3 (SCA3) is a progressive neurodegenerative disorder caused by expansion of the polyglutamine repeat in the ataxin-3 protein. Expression of mutant ataxin-3 is known to result in transcriptional dysregulation, which can contribute to the cellular toxicity and n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toonen, Lodewijk J. A., Overzier, Maurice, Evers, Melvin M., Leon, Leticia G., van der Zeeuw, Sander A. J., Mei, Hailiang, Kielbasa, Szymon M., Goeman, Jelle J., Hettne, Kristina M., Magnusson, Olafur Th., Poirel, Marion, Seyer, Alexandre, ‘t Hoen, Peter A. C., van Roon-Mom, Willeke M. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013885/ https://www.ncbi.nlm.nih.gov/pubmed/29929540 http://dx.doi.org/10.1186/s13024-018-0261-9

Ejemplares similares

Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies
por: Evers, Melvin M., et al.
Publicado: (2013)

Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3
por: Toonen, Lodewijk J. A., et al.
Publicado: (2016)

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
por: Buijsen, Ronald A.M., et al.
Publicado: (2019)

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
por: Toonen, Lodewijk J.A., et al.
Publicado: (2017)

Common disease signatures from gene expression analysis in Huntington’s disease human blood and brain
por: Mina, Eleni, et al.
Publicado: (2016)

Therapeutic Strategies for Spinocerebellar Ataxia Type 1
por: Kerkhof, Laurie M. C., et al.
Publicado: (2023)

Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain
por: Toonen, Lodewijk J.A., et al.
Publicado: (2018)

Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias
por: Hommersom, Marina P., et al.
Publicado: (2021)

Statistical method for modeling sequencing data from different technologies in longitudinal studies with application to Huntington disease
por: Fuady, Angga M., et al.
Publicado: (2020)

Brain Transcriptomic Analysis of Hereditary Cerebral Hemorrhage With Amyloidosis-Dutch Type
por: Grand Moursel, Laure, et al.
Publicado: (2018)

The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study
por: van Prooije, Teije, et al.
Publicado: (2023)

Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood
por: Mastrokolias, Anastasios, et al.
Publicado: (2015)

Correction to: The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study
por: van Prooije, Teije, et al.
Publicado: (2023)

Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington’s disease peripheral blood samples
por: Mastrokolias, Anastasios, et al.
Publicado: (2016)

Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3
por: Koike, Yuka, et al.
Publicado: (2021)

Exploring the Transcriptome of Ciliated Cells Using In Silico Dissection of Human Tissues
por: Ivliev, Alexander E., et al.
Publicado: (2012)

Ataxin-3 phosphorylation decreases neuronal defects in spinocerebellar ataxia type 3 models
por: Matos, Carlos A., et al.
Publicado: (2016)

Identification of the ataxin-1 interaction network and its impact on spinocerebellar ataxia type 1
por: Chen, Jiu-Ming, et al.
Publicado: (2022)

Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain
por: Zalachoras, Ioannis, et al.
Publicado: (2011)

Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA
por: Mastrokolias, Anastasios, et al.
Publicado: (2012)

Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model
por: Duncan, Carlotta E, et al.
Publicado: (2013)

Partial Loss of Ataxin-1 Function Contributes to Transcriptional Dysregulation in Spinocerebellar Ataxia Type 1 Pathogenesis
por: Crespo-Barreto, Juan, et al.
Publicado: (2010)

Ataxin-3, The Spinocerebellar Ataxia Type 3 Neurodegenerative Disorder Protein, Affects Mast Cell Functions
por: Sowa, Anna S., et al.
Publicado: (2022)

Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3
por: Menzies, Fiona M., et al.
Publicado: (2010)

The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
por: Heinz, Annika, et al.
Publicado: (2021)

Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3
por: Johnson, Sean L., et al.
Publicado: (2021)

Mutant Ataxin-2 Expression in Aged Animals Aggravates Neuropathological Features Associated with Spinocerebellar Ataxia Type 2
por: Afonso, Inês T., et al.
Publicado: (2022)

Cross‐sectional serum metabolomic study of multiple forms of muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2018)

Simultaneous Enrichment Analysis of all Possible Gene-sets: Unifying Self-Contained and Competitive Methods
por: Ebrahimpoor, Mitra, et al.
Publicado: (2019)

Making (anti-) sense out of huntingtin levels in Huntington disease
por: Evers, Melvin M, et al.
Publicado: (2015)

Cerebellar Soluble Mutant Ataxin-3 Level Decreases during Disease Progression in Spinocerebellar Ataxia Type 3 Mice
por: Nguyen, Huu Phuc, et al.
Publicado: (2013)

TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2
por: Bux, Jessica, et al.
Publicado: (2023)

Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review
por: Bakels, Hannah S., et al.
Publicado: (2021)

Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2015)

Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease
por: van Roon-Mom, Willeke MC, et al.
Publicado: (2008)

Ubiquitin-binding site 1 of pathogenic ataxin-3 regulates its toxicity in Drosophila models of Spinocerebellar Ataxia Type 3
por: Prifti, Matthew V., et al.
Publicado: (2023)

miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3
por: Nobre, Rui Jorge, et al.
Publicado: (2022)

Osteopontin and phospho‐SMAD2/3 are associated with calcification of vessels in D‐CAA, an hereditary cerebral amyloid angiopathy
por: Grand Moursel, Laure, et al.
Publicado: (2019)

Indirect Negative Effect of Mutant Ataxin-1 on Short- and Long-Term Synaptic Plasticity in Mouse Models of Spinocerebellar Ataxia Type 1
por: Shuvaev, Anton N., et al.
Publicado: (2022)

Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide
por: Evers, Melvin M., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_v6vf76pphdbc6tirgp0m248l2v